Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress
Hematopoietic stem cells (HSCs) with superior reconstitution potential are reported to be enriched in the endosteal compared to central bone marrow (BM) region. To investigate whether specific factors at the endosteum may contribute to HSC potency, we screened for candidate HSC niche factors enriche...
Gespeichert in:
| Veröffentlicht in: | Stem cells (Dayton, Ohio) Ohio), 2021-11, Vol.39 (11), p.1532-1545 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1545 |
|---|---|
| container_issue | 11 |
| container_start_page | 1532 |
| container_title | Stem cells (Dayton, Ohio) |
| container_volume | 39 |
| creator | Tay, Joshua Barbier, Valerie Helwani, Falak M. Price, Gareth R. Levesque, Jean‐Pierre Winkler, Ingrid G. |
| description | Hematopoietic stem cells (HSCs) with superior reconstitution potential are reported to be enriched in the endosteal compared to central bone marrow (BM) region. To investigate whether specific factors at the endosteum may contribute to HSC potency, we screened for candidate HSC niche factors enriched in the endosteal compared to central BM regions. Together with key known HSC supporting factors Kitl and Cxcl12, we report that prostacyclin/prostaglandin I2 (PGI2) synthase (Ptgis) was one of the most highly enriched mRNAs (>10‐fold) in endosteal compared to central BM. As PGI2 signals through receptors distinct from prostaglandin E2 (PGE2), we investigated functional roles for PGI2 at the endosteal niche using therapeutic PGI2 analogs, iloprost, and cicaprost. We found PGI2 analogs strongly reduced HSC differentiation in vitro. Ex vivo iloprost pulse treatment also significantly boosted long‐term competitive repopulation (LT‐CR) potential of HSCs upon transplantation. This was associated with increased tyrosine‐phosphorylation of transducer and activator of transcription‐3 (STAT3) signaling in HSCs but not altered cell cycling. In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony‐stimulating factor‐induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM. In conclusion, we propose that PGI2 is a novel HSC regulator enriched in the endosteum that promotes HSC regenerative potential following stress.
Prostacyclin/prostaglandin I2 (PGI2) is a novel hematopoietic stem cell (HSC) regulatory factor enriched at the endosteum. PGI2 is synthesized by prostacyclin syntase (PTGIS) expressed mainly by osteoblasts, mesenchymal stromal cells and endothelial cells. Ex vivo and in vivo treatment with PGI2 analogs enhance HSC long‐term competitive repopulation potential and protect reconstituting HSC from stress. |
| doi_str_mv | 10.1002/stem.3438 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2552060784</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2586544783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-ace16b6ef413d3a88dbf3dbeaf3977259c53a99f358a1d5ae3e970bb2b86a6ee3</originalsourceid><addsrcrecordid>eNp1kctu1jAQhS0EohdY8ALIEhtYpLXjS-wlqgpFKmolyjpynEnrKrFD7Kj6X4Mn7oS_sEDqxrZmvjma40PIO85OOGP1aS4wnQgpzAtyyJW0lbTcvMQ307pSzNoDcpTzPWNcKmNekwMha80MU4fk9_WScnF-58cQacjURQqxxxq4kXYpAp3csqQHGoO_A-rTNGMxFgR7Gkqm22DwCLvoxnRLw5jmTZPiWcAjcQeTK2lOAUrwdFuWehhHOmM_loCj_bqEeIutBXJ-Q14Nbszw9uk-Jj-_nN-cXVSXV1-_nX2-rLwwxlTOA9edhkFy0QtnTN8Nou_ADcI2Ta2sV8JZOwhlHO-VAwG2YV1Xd0Y7DSCOyce9Li76a4Vc2inkbTEXIa25rZWqmWaNkYh--A-9T-uCfjfKaCVlYwRSn_aUR_95gaGdl4C_t2s5a7eg2s17uwWF7PsnxbWboP9H_k0GgdM98BBG2D2v1P64Of_-R_IRuTKh4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586544783</pqid></control><display><type>article</type><title>Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tay, Joshua ; Barbier, Valerie ; Helwani, Falak M. ; Price, Gareth R. ; Levesque, Jean‐Pierre ; Winkler, Ingrid G.</creator><creatorcontrib>Tay, Joshua ; Barbier, Valerie ; Helwani, Falak M. ; Price, Gareth R. ; Levesque, Jean‐Pierre ; Winkler, Ingrid G.</creatorcontrib><description>Hematopoietic stem cells (HSCs) with superior reconstitution potential are reported to be enriched in the endosteal compared to central bone marrow (BM) region. To investigate whether specific factors at the endosteum may contribute to HSC potency, we screened for candidate HSC niche factors enriched in the endosteal compared to central BM regions. Together with key known HSC supporting factors Kitl and Cxcl12, we report that prostacyclin/prostaglandin I2 (PGI2) synthase (Ptgis) was one of the most highly enriched mRNAs (>10‐fold) in endosteal compared to central BM. As PGI2 signals through receptors distinct from prostaglandin E2 (PGE2), we investigated functional roles for PGI2 at the endosteal niche using therapeutic PGI2 analogs, iloprost, and cicaprost. We found PGI2 analogs strongly reduced HSC differentiation in vitro. Ex vivo iloprost pulse treatment also significantly boosted long‐term competitive repopulation (LT‐CR) potential of HSCs upon transplantation. This was associated with increased tyrosine‐phosphorylation of transducer and activator of transcription‐3 (STAT3) signaling in HSCs but not altered cell cycling. In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony‐stimulating factor‐induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM. In conclusion, we propose that PGI2 is a novel HSC regulator enriched in the endosteum that promotes HSC regenerative potential following stress.
Prostacyclin/prostaglandin I2 (PGI2) is a novel hematopoietic stem cell (HSC) regulatory factor enriched at the endosteum. PGI2 is synthesized by prostacyclin syntase (PTGIS) expressed mainly by osteoblasts, mesenchymal stromal cells and endothelial cells. Ex vivo and in vivo treatment with PGI2 analogs enhance HSC long‐term competitive repopulation potential and protect reconstituting HSC from stress.</description><identifier>ISSN: 1066-5099</identifier><identifier>EISSN: 1549-4918</identifier><identifier>DOI: 10.1002/stem.3438</identifier><identifier>PMID: 34260805</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Analogs ; Bone Marrow ; CXCL12 protein ; Enrichment ; Epoprostenol - pharmacology ; G‐CSF ; hematopoietic stem cell transplantation ; Hematopoietic Stem Cells ; HSCs ; Iloprost - pharmacology ; irradiation ; Leukocytes (granulocytic) ; long‐term repopulation ; microenvironment ; Phosphorylation ; Prostacyclin ; Prostaglandin E2 ; Radiation ; Repopulation ; Stat3 protein ; Stem Cell Niche - physiology ; Stem cells ; stem cell‐microenvironment interactions ; Transcription ; Transplantation ; Tyrosine</subject><ispartof>Stem cells (Dayton, Ohio), 2021-11, Vol.39 (11), p.1532-1545</ispartof><rights>2021 AlphaMed Press.</rights><rights>2021 AlphaMed Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-ace16b6ef413d3a88dbf3dbeaf3977259c53a99f358a1d5ae3e970bb2b86a6ee3</citedby><cites>FETCH-LOGICAL-c3888-ace16b6ef413d3a88dbf3dbeaf3977259c53a99f358a1d5ae3e970bb2b86a6ee3</cites><orcidid>0000-0002-0851-0537</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34260805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tay, Joshua</creatorcontrib><creatorcontrib>Barbier, Valerie</creatorcontrib><creatorcontrib>Helwani, Falak M.</creatorcontrib><creatorcontrib>Price, Gareth R.</creatorcontrib><creatorcontrib>Levesque, Jean‐Pierre</creatorcontrib><creatorcontrib>Winkler, Ingrid G.</creatorcontrib><title>Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress</title><title>Stem cells (Dayton, Ohio)</title><addtitle>Stem Cells</addtitle><description>Hematopoietic stem cells (HSCs) with superior reconstitution potential are reported to be enriched in the endosteal compared to central bone marrow (BM) region. To investigate whether specific factors at the endosteum may contribute to HSC potency, we screened for candidate HSC niche factors enriched in the endosteal compared to central BM regions. Together with key known HSC supporting factors Kitl and Cxcl12, we report that prostacyclin/prostaglandin I2 (PGI2) synthase (Ptgis) was one of the most highly enriched mRNAs (>10‐fold) in endosteal compared to central BM. As PGI2 signals through receptors distinct from prostaglandin E2 (PGE2), we investigated functional roles for PGI2 at the endosteal niche using therapeutic PGI2 analogs, iloprost, and cicaprost. We found PGI2 analogs strongly reduced HSC differentiation in vitro. Ex vivo iloprost pulse treatment also significantly boosted long‐term competitive repopulation (LT‐CR) potential of HSCs upon transplantation. This was associated with increased tyrosine‐phosphorylation of transducer and activator of transcription‐3 (STAT3) signaling in HSCs but not altered cell cycling. In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony‐stimulating factor‐induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM. In conclusion, we propose that PGI2 is a novel HSC regulator enriched in the endosteum that promotes HSC regenerative potential following stress.
Prostacyclin/prostaglandin I2 (PGI2) is a novel hematopoietic stem cell (HSC) regulatory factor enriched at the endosteum. PGI2 is synthesized by prostacyclin syntase (PTGIS) expressed mainly by osteoblasts, mesenchymal stromal cells and endothelial cells. Ex vivo and in vivo treatment with PGI2 analogs enhance HSC long‐term competitive repopulation potential and protect reconstituting HSC from stress.</description><subject>Analogs</subject><subject>Bone Marrow</subject><subject>CXCL12 protein</subject><subject>Enrichment</subject><subject>Epoprostenol - pharmacology</subject><subject>G‐CSF</subject><subject>hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cells</subject><subject>HSCs</subject><subject>Iloprost - pharmacology</subject><subject>irradiation</subject><subject>Leukocytes (granulocytic)</subject><subject>long‐term repopulation</subject><subject>microenvironment</subject><subject>Phosphorylation</subject><subject>Prostacyclin</subject><subject>Prostaglandin E2</subject><subject>Radiation</subject><subject>Repopulation</subject><subject>Stat3 protein</subject><subject>Stem Cell Niche - physiology</subject><subject>Stem cells</subject><subject>stem cell‐microenvironment interactions</subject><subject>Transcription</subject><subject>Transplantation</subject><subject>Tyrosine</subject><issn>1066-5099</issn><issn>1549-4918</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctu1jAQhS0EohdY8ALIEhtYpLXjS-wlqgpFKmolyjpynEnrKrFD7Kj6X4Mn7oS_sEDqxrZmvjma40PIO85OOGP1aS4wnQgpzAtyyJW0lbTcvMQ307pSzNoDcpTzPWNcKmNekwMha80MU4fk9_WScnF-58cQacjURQqxxxq4kXYpAp3csqQHGoO_A-rTNGMxFgR7Gkqm22DwCLvoxnRLw5jmTZPiWcAjcQeTK2lOAUrwdFuWehhHOmM_loCj_bqEeIutBXJ-Q14Nbszw9uk-Jj-_nN-cXVSXV1-_nX2-rLwwxlTOA9edhkFy0QtnTN8Nou_ADcI2Ta2sV8JZOwhlHO-VAwG2YV1Xd0Y7DSCOyce9Li76a4Vc2inkbTEXIa25rZWqmWaNkYh--A-9T-uCfjfKaCVlYwRSn_aUR_95gaGdl4C_t2s5a7eg2s17uwWF7PsnxbWboP9H_k0GgdM98BBG2D2v1P64Of_-R_IRuTKh4A</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Tay, Joshua</creator><creator>Barbier, Valerie</creator><creator>Helwani, Falak M.</creator><creator>Price, Gareth R.</creator><creator>Levesque, Jean‐Pierre</creator><creator>Winkler, Ingrid G.</creator><general>John Wiley & Sons, Inc</general><general>Oxford University Press</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0851-0537</orcidid></search><sort><creationdate>202111</creationdate><title>Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress</title><author>Tay, Joshua ; Barbier, Valerie ; Helwani, Falak M. ; Price, Gareth R. ; Levesque, Jean‐Pierre ; Winkler, Ingrid G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-ace16b6ef413d3a88dbf3dbeaf3977259c53a99f358a1d5ae3e970bb2b86a6ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analogs</topic><topic>Bone Marrow</topic><topic>CXCL12 protein</topic><topic>Enrichment</topic><topic>Epoprostenol - pharmacology</topic><topic>G‐CSF</topic><topic>hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cells</topic><topic>HSCs</topic><topic>Iloprost - pharmacology</topic><topic>irradiation</topic><topic>Leukocytes (granulocytic)</topic><topic>long‐term repopulation</topic><topic>microenvironment</topic><topic>Phosphorylation</topic><topic>Prostacyclin</topic><topic>Prostaglandin E2</topic><topic>Radiation</topic><topic>Repopulation</topic><topic>Stat3 protein</topic><topic>Stem Cell Niche - physiology</topic><topic>Stem cells</topic><topic>stem cell‐microenvironment interactions</topic><topic>Transcription</topic><topic>Transplantation</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tay, Joshua</creatorcontrib><creatorcontrib>Barbier, Valerie</creatorcontrib><creatorcontrib>Helwani, Falak M.</creatorcontrib><creatorcontrib>Price, Gareth R.</creatorcontrib><creatorcontrib>Levesque, Jean‐Pierre</creatorcontrib><creatorcontrib>Winkler, Ingrid G.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Stem cells (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tay, Joshua</au><au>Barbier, Valerie</au><au>Helwani, Falak M.</au><au>Price, Gareth R.</au><au>Levesque, Jean‐Pierre</au><au>Winkler, Ingrid G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress</atitle><jtitle>Stem cells (Dayton, Ohio)</jtitle><addtitle>Stem Cells</addtitle><date>2021-11</date><risdate>2021</risdate><volume>39</volume><issue>11</issue><spage>1532</spage><epage>1545</epage><pages>1532-1545</pages><issn>1066-5099</issn><eissn>1549-4918</eissn><abstract>Hematopoietic stem cells (HSCs) with superior reconstitution potential are reported to be enriched in the endosteal compared to central bone marrow (BM) region. To investigate whether specific factors at the endosteum may contribute to HSC potency, we screened for candidate HSC niche factors enriched in the endosteal compared to central BM regions. Together with key known HSC supporting factors Kitl and Cxcl12, we report that prostacyclin/prostaglandin I2 (PGI2) synthase (Ptgis) was one of the most highly enriched mRNAs (>10‐fold) in endosteal compared to central BM. As PGI2 signals through receptors distinct from prostaglandin E2 (PGE2), we investigated functional roles for PGI2 at the endosteal niche using therapeutic PGI2 analogs, iloprost, and cicaprost. We found PGI2 analogs strongly reduced HSC differentiation in vitro. Ex vivo iloprost pulse treatment also significantly boosted long‐term competitive repopulation (LT‐CR) potential of HSCs upon transplantation. This was associated with increased tyrosine‐phosphorylation of transducer and activator of transcription‐3 (STAT3) signaling in HSCs but not altered cell cycling. In vivo, iloprost administration protected BM HSC potential from radiation or granulocyte colony‐stimulating factor‐induced exhaustion, and restored HSC homing potential with increased Kitl and Cxcl12 transcription in the BM. In conclusion, we propose that PGI2 is a novel HSC regulator enriched in the endosteum that promotes HSC regenerative potential following stress.
Prostacyclin/prostaglandin I2 (PGI2) is a novel hematopoietic stem cell (HSC) regulatory factor enriched at the endosteum. PGI2 is synthesized by prostacyclin syntase (PTGIS) expressed mainly by osteoblasts, mesenchymal stromal cells and endothelial cells. Ex vivo and in vivo treatment with PGI2 analogs enhance HSC long‐term competitive repopulation potential and protect reconstituting HSC from stress.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34260805</pmid><doi>10.1002/stem.3438</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-0851-0537</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1066-5099 |
| ispartof | Stem cells (Dayton, Ohio), 2021-11, Vol.39 (11), p.1532-1545 |
| issn | 1066-5099 1549-4918 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2552060784 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Analogs Bone Marrow CXCL12 protein Enrichment Epoprostenol - pharmacology G‐CSF hematopoietic stem cell transplantation Hematopoietic Stem Cells HSCs Iloprost - pharmacology irradiation Leukocytes (granulocytic) long‐term repopulation microenvironment Phosphorylation Prostacyclin Prostaglandin E2 Radiation Repopulation Stat3 protein Stem Cell Niche - physiology Stem cells stem cell‐microenvironment interactions Transcription Transplantation Tyrosine |
| title | Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T00%3A24%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostacyclin%20is%20an%20endosteal%20bone%20marrow%20niche%20component%20and%20its%20clinical%20analog%20iloprost%20protects%20hematopoietic%20stem%20cell%20potential%20during%20stress&rft.jtitle=Stem%20cells%20(Dayton,%20Ohio)&rft.au=Tay,%20Joshua&rft.date=2021-11&rft.volume=39&rft.issue=11&rft.spage=1532&rft.epage=1545&rft.pages=1532-1545&rft.issn=1066-5099&rft.eissn=1549-4918&rft_id=info:doi/10.1002/stem.3438&rft_dat=%3Cproquest_cross%3E2586544783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586544783&rft_id=info:pmid/34260805&rfr_iscdi=true |